Host Factors in HPV-related Carcinogenesis: Cellular Mechanisms Controlling HPV Infections

Archives of Medical Research

Volumn 40, Issue 6, 2009, Pages 435-442

  von Knebel Doeberitz, Magnus ^a   Vinokurova, Svetlana ^a  

^a Institute of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN E6; PROTEIN E7;

CANCER CELL CULTURE; CANCER RISK; CELL CLONE; CELL DIFFERENTIATION; DISEASE ASSOCIATION; EPIGENETICS; GENE EXPRESSION; HOST CELL; HOST PATHOGEN INTERACTION; HUMAN; INFECTION CONTROL; LATENT VIRUS INFECTION; LIFE CYCLE; PERSISTENT VIRUS INFECTION; REVIEW; SQUAMOUS CELL; TUMOR GROWTH; UTERINE CERVIX CARCINOMA; VIRUS CARCINOGENESIS; VIRUS ENTRY; VIRUS GENE; VIRUS GENOME; VIRUS REPLICATION; WART VIRUS;

FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; UTERINE CERVICAL NEOPLASMS;

EID: 70350057115     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2009.06.002     Document Type: Review

References (63)

1. Schiffman M., Castle P.E., Jeronimo J., et al. Human papillomavirus and cervical cancer. Lancet 370 (2007) 890-907
2. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2 (2002) 342-350
3. Munger K., and Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res 89 (2002) 213-228
4. zur Hausen H. Intracellular surveillance of persisting viral infections. Human genital cancer results from deficient cellular control of papillomavirus gene expression. Lancet 2 (1986) 489-491
5. Chow L.T., Duffy A.A., Wang H.K., et al. A highly efficient system to produce infectious human papillomavirus: elucidation of natural virus-host interactions. Cell Cycle 8 (2009) 1319-1323
6. Wang H.K., Duffy A.A., Broker T.R., et al. Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes Dev 23 (2009) 181-194
7. Thierry F. Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical carcinoma. Virology 384 (2009) 375-379
8. Selinka H.C., Florin L., Patel H.D., et al. Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol 81 (2007) 10970-10980
9. Schelhaas M., Ewers H., Rajamaki M.L., et al. Human papillomavirus type 16 entry: retrograde cell surface transport along actin-rich protrusions. PLoS Pathog 4 (2008) e1000148
10. Day P.M., Lowy D.R., and Schiller J.T. Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 307 (2003) 1-11
11. Smith J.L., Campos S.K., and Ozbun M.A. Human papillomavirus type 31 uses a caveolin 1- and dynamin 2-mediated entry pathway for infection of human keratinocytes. J Virol 81 (2007) 9922-9931
12. Smith J.L., Campos S.K., Wandinger-Ness A., et al. Caveolin-1-dependent infectious entry of human papillomavirus type 31 in human keratinocytes proceeds to the endosomal pathway for pH-dependent uncoating. J Virol 82 (2008) 9505-9512
13. Stoler M.H., and Broker T.R. In situ hybridization detection of human papillomavirus DNAs and messenger RNAs in genital condylomas and a cervical carcinoma. Hum Pathol 17 (1986) 1250-1258
14. Stoler M.H., Wolinsky S.M., Whitbeck A., et al. Differentiation-linked human papillomavirus types 6 and 11 transcription in genital condylomata revealed by in situ hybridization with message-specific RNA probes. Virology 172 (1989) 331-340
15. Stoler M.H., Rhodes C.R., Whitbeck A., et al. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 23 (1992) 117-128
16. Cameron J.E., and Hagensee M.E. Human papillomavirus infection and disease in the HIV+ individual. Cancer Treat Res 133 (2007) 185-213
17. Pfister H. Chapter 8: Human papillomavirus and skin cancer. J Natl Cancer Inst Monogr (2003) 52-56
18. Orth G., Favre M., Majewski S., et al. Epidermodysplasia verruciformis defines a subset of cutaneous human papillomaviruses. J Virol 75 (2001) 4952-4953
19. Ramoz N., Rueda L.A., Bouadjar B., et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 32 (2002) 579-581
20. Doorbar J. Papillomavirus life cycle organization and biomarker selection. Dis Markers 23 (2007) 297-313
21. Longworth M.S., and Laimins L.A. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 68 (2004) 362-372
22. Middleton K., Peh W., Southern S., et al. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol 77 (2003) 10186-10201
23. Hebner C.M., and Laimins L.A. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 16 (2006) 83-97
24. Steger G., and Corbach S. Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein. J Virol 71 (1997) 50-58
25. Kruppel U., Muller-Schiffmann A., Baldus S.E., et al. E2 and the co-activator p300 can cooperate in activation of the human papillomavirus type 16 early promoter. Virology 377 (2008) 151-159
26. You J., Croyle J.L., Nishimura A., et al. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 117 (2004) 349-360
27. Cheng S., Schmidt-Grimminger D.C., Murant T., et al. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev 9 (1995) 2335-2349
28. Jia R., Liu X., Tao M., et al. Control of the papillomavirus early-to-late switch by differentially expressed SRp20. J Virol 83 (2009) 167-180
29. Stanley M.A. Immunobiology of papillomavirus infections. J Reprod Immunol 52 (2001) 45-59
30. Strickler H.D., Burk R.D., Fazzari M., et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 97 (2005) 577-586
31. Duensing S., and Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 109 (2004) 157-162
32. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92 (2000) 690-698
33. Kadaja M., Isok-Paas H., Laos T., et al. Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses. PLoS Pathog 5 (2009) e1000397
34. Pett M., and Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis?. J Pathol 212 (2007) 356-367
35. Woodman C.B., Collins S.I., and Young L.S. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7 (2007) 11-22
36. Klaes R., Woerner S.M., Ridder R., et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 59 (1999) 6132-6136
37. Vinokurova S., Wentzensen N., Kraus I., et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 68 (2008) 307-313
38. Melsheimer P., Vinokurova S., Wentzensen N., et al. DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Clin. Cancer Res 10 (2004) 3059-3063
39. Arias-Pulido H., Peyton C.L., Joste N.E., et al. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol 44 (2006) 1755-1762
40. Collado M., Blasco M.A., and Serrano M. Cellular senescence in cancer and aging. Cell 130 (2007) 223-233
41. Khleif S.N., DeGregori J., Yee C.L., et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA 93 (1996) 4350-4354
42. Sano T., Oyama T., Kashiwabara K., et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 153 (1998) 1741-1748
43. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 38 (2002) 2229-2242
44. Wentzensen N., and von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis Markers 23 (2007) 315-330
45. Schrump D.S., Chen G.A., Consuli U., et al. Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16INK4. Cancer Gene Ther 3 (1996) 357-364
46. Klaes R., Friedrich T., Spitkovsky D., et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 92 (2001) 276-284
47. Ballestar E., and Esteller M. SnapShot: the human DNA methylome in health and disease. Cell 135 (2008) 1144
48. Feinberg A.P. Phenotypic plasticity and the epigenetics of human disease. Nature 447 (2007) 433-440
49. Bernstein B.E., Meissner A., and Lander E.S. The mammalian epigenome. Cell 128 (2007) 669-681
50. Meissner A., Mikkelsen T.S., Gu H., et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454 (2008) 766-770
51. Feinberg A.P. An epigenetic approach to cancer etiology. Cancer J 13 (2007) 70-74
52. Klose R.J., and Bird A.P. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 31 (2006) 89-97
53. Badal S., Badal V., Calleja-Macias I.E., et al. The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation. Virology 324 (2004) 483-492
54. Badal V., Chuang L.S., Tan E.H., et al. CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. J Virol 77 (2003) 6227-6234
55. Bhattacharjee B., and Sengupta S. CpG methylation of HPV 16 LCR at E2 binding site proximal to P97 is associated with cervical cancer in presence of intact E2. Virology 354 (2006) 280-285
56. Fernandez A.F., Rosales C., Lopez-Nieva P., et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 19 (2009) 438-451
57. Kalantari M., Calleja-Macias I.E., Tewari D., et al. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol 78 (2004) 12762-12772
58. Kalantari M., Lee D., Calleja-Macias I.E., et al. Effects of cellular differentiation, chromosomal integration and 5-aza-2′-deoxycytidine treatment on human papillomavirus-16 DNA methylation in cultured cell lines. Virology 374 (2008) 292-303
59. Turan T., Kalantari M., Calleja-Macias I.E., et al. Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression?. Virology 349 (2006) 175-183
60. Turan T., Kalantari M., Cuschieri K., et al. High-throughput detection of human papillomavirus-18 L1 gene methylation, a candidate biomarker for the progression of cervical neoplasia. Virology 361 (2007) 185-193
61. Kim K., Garner-Hamrick P.A., Fisher C., et al. Methylation patterns of papillomavirus DNA, its influence on E2 function, and implications in viral infection. J Virol 77 (2003) 12450-12459
62. Doerfler W. In pursuit of the first recognized epigenetic signal-DNA methylation: a 1976 to 2008 synopsis. Epigenetics 3 (2008) 125-133
63. Danos O., Katinka M., and Yaniv M. Molecular cloning, refined physical map and heterogeneity of methylation sites of papilloma virus type 1a DNA. Eur J Biochem 109 (1980) 457-461